This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Parallel improvement of cognitive functions and P300 latency following donepezil treatment in patients with Alzheimer’s disease: a case-control study


Chang, Yu-San, Chen, Hsiang-Lan, Hsu, Chung-Yao, Tang, Shu-Hui, Liu, Ching-Kuan


Journal Of Clinical Neurophysiology: Official Publication Of The American Electroencephalographic Society, Volume: 31, No.: 1, Pages.: 81-85

Year of Publication



Purpose: To evaluate the effect of donepezil, one of the cholinesterase inhibitors, on P300 measurements in patients with Alzheimer’s disease (AD) and investigate the relationship between the subfactors of cognitive performance and P300 components.; Methods: One hundred outpatients with AD were evaluated for cognitive function (cognitive ability screening instrument) and event-related potentials before and after 22 to 23 weeks of treatment with donepezil (5 mg/day). Twenty age-matched normal control subjects were recruited.; Results: The patients with AD showed prolonged P300 and N200 latency, no significant differences in N100 and P200 components, and poor performance in neuropsychological assessments compared with control subjects at baseline. After donepezil treatment, the patients with AD had reduction in P300 latency at Pz lead, which was associated with a parallel improvement in cognitive function in terms of remote memory, recent memory, visual instruction, and orientation. The pre-post treatment difference of P300 latency significantly correlated with the cognitive ability screening instrument score difference and recent memory score difference, respectively.; Conclusions: The patients with AD still had intact early sensory processing but impaired higher-level cognitive processes that could influence behavior deviation. The donepezil treatment, which enhances higher-level cognitive processing time, revealed that P300 latency decreases as cognitive capability increases, especially improved in recent memory.;

Bibtex Citation

@article{Chang_2014, doi = {10.1097/01.wnp.0000436899.48243.5e}, url = {}, year = 2014, month = {feb}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {31}, number = {1}, pages = {81--85}, author = {Yu-San Chang and Hsiang-Lan Chen and Chung-Yao Hsu and Shu-Hui Tang and Ching-Kuan Liu}, title = {Parallel Improvement of Cognitive Functions and P300 Latency Following Donepezil Treatment in Patients With Alzheimer's Disease}, journal = {Journal of Clinical Neurophysiology} }


aged, aged, 80 and over, alzheimer disease, cholinesterase inhibitors, cognition, donepezil, drug effects, drug therapy, eventrelated potentials p300, evoked potentials, female, humans, indans, male, physiology, physiopathology, piperidines, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime